Literature DB >> 10365638

Valproic acid toxicokinetics: serial hemodialysis and hemoperfusion.

E J Franssen1, G G van Essen, A T Portman, J de Jong, G Go, C A Stegeman, D R Uges.   

Abstract

The toxicity and pharmacokinetic properties of a drug determine whether hemodialysis and/or hemoperfusion are indicated in acute intoxications. Valproic acid is considered unremovable by hemodialysis because of the high protein binding of 90%-95%. A 27-year-old male with a history of seizures was admitted to the emergency room because of coma, hypernatriemia, and respiratory failure caused by an intoxication with a large dose of valproic acid. At admission, the plasma valproic acid level was 1414 mg/L (9.9 mmol/L) (therapeutic range: 50-100 mg/L (350-700 micromol/ L). The anion gap was 26 mmol/L (normal <12-14 mmol/L) and corresponded fairly well with this valproic acid level. Because of the potential toxicity of this high valproic acid level serial hemodialysis and hemoperfusion was performed. The first session was done with a charcoal column and the second session with a resin column. The patient recovered during the course of treatment. The valproic acid plasma clearances during treatment were: 80 mL/min (hemodialysis); 40 mL/min (hemoperfusion by charcoal) and 80 mL/min (hemoperfusion by resin, only in the first hour). The protein binding of valproic acid in plasma was only 32% at the start and was 54% at the end of the two sessions. In this specific case of a severe valproic acid intoxication, saturated protein binding resulted in an increased fraction of unbound valproic acid. This made hemodialysis an effective treatment, while hemoperfusion was relatively less effective because of saturation of the column. In conclusion, the toxicokinetics of valproate are quite different from the pharmacokinetics at therapeutic levels. The anion gap and protein binding are important parameters in toxicokinetics.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10365638     DOI: 10.1097/00007691-199906000-00005

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

1.  Case files of the Children's Hospital of Michigan Regional Poison Control Center: the use of carnitine for the management of acute valproic acid toxicity.

Authors:  Abhishek Katiyar; Cynthia Aaron
Journal:  J Med Toxicol       Date:  2007-09

2.  Case Files of the University of California, San Francisco Medical Toxicology Fellowship: Seizures and a Persistent Anion Gap Metabolic Acidosis.

Authors:  Ann Arens; Craig Smollin
Journal:  J Med Toxicol       Date:  2016-04-14

3.  Extracorporeal elimination in acute valproate intoxication.

Authors:  Els A van der Wouden; Angela Dekkers; Hannah M E Kruis; Ingeborg M van Geijlswijk; David H Tjan; Geert W Feith
Journal:  BMJ Case Rep       Date:  2009-02-02

4.  Low-dose valproic acid with low-dose gemcitabine augments MHC class I-related chain A/B expression without inducing the release of soluble MHC class I-related chain A/B.

Authors:  Tomoharu Miyashita; Kenji Miki; Takashi Kamigaki; Isamu Makino; Hidehiro Tajima; Shinichi Nakanuma; Hironori Hayashi; Hiroyuki Takamura; Sachio Fushida; Ali K Ahmed; John W Harmon; Tetsuo Ohta
Journal:  Oncol Lett       Date:  2017-09-14       Impact factor: 2.967

5.  Hemodiafiltration Treatment for Severe Valproic Acid Intoxication: Case Report and Updated Systematic Literature Review.

Authors:  Tobias Tichelbäcker; Judith Herath; Björn Tampe; Peter Korsten
Journal:  Front Med (Lausanne)       Date:  2018-08-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.